Clinical Trials
15
Active:7
Completed:7
Trial Phases
2 Phases
Phase 1:5
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (62.5%)Phase 2
3 (37.5%)Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
Phase 2
Completed
- Conditions
- Acute PyelonephritisUrinary Tract Infections
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 225
- Registration Number
- NCT01928433
- Locations
- 🇩🇪
Universitätsklinikum Giessen, Klinik für Urologie, Kinderurologie und Andrologie, Giessen, Germany
Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 58
- Registration Number
- NCT01910883
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
Phase 1
Completed
- Conditions
- Safety and Tolerability
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 18
- Registration Number
- NCT01907867
- Locations
- 🇺🇸
Pulmonary Associates, PA, Phoenix, Arizona, United States
Effect of Age and Gender on the PK and Tolerability of Finafloxacin
Phase 1
Completed
- Conditions
- Pharmacokinetic and Tolerability of Finafloxacin
- Interventions
- Drug: 400 mg finafloxacin (2 x 200 mg tablets)
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT01904162
- Locations
- 🇺🇸
Celerion (formerly MDS Pharmaservices), Tempe, Arizona, United States
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
Phase 2
Completed
- Conditions
- Gram-Negative Bacterial InfectionsHelicobacter InfectionsDyspepsia
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT00723502
- Locations
- 🇩🇪
Dr. Hein, Marburg, Germany
- Prev
- 1
- 2
- Next
News
No news found